Blueprint Medicines Corporation Stock News

Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Both companies have catalysts for explosive growth this year.

Both companies have catalysts for explosive growth this year.

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines Corporation (NASDAQ:BPMC) shares, rose in value on Friday, 03/11/22, with the stock price up by 0.11% to the previous day’s close as strong demand from buyers drove the stock to $57.10. Actively observing the price movement in the last trading, the stock closed the session at $57.04, falling within a range of $57.00 … What Analysts Were Expecting After Blueprint Medicines Corporation (NASDAQ: BPMC) rose 0.11% Read More »

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the

The trading price of Blueprint Medicines Corporation (NASDAQ:BPMC) closed higher on Tuesday, March 08, closing at $55.55, 2.68% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $53.26 … Blueprint Medicines Corporation’s Stock Gains 2.68%, But It May Still Be Worth Investing In. Read More »

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across its precision therapy portfolio at the American Association for Cancer Research (AACR) Annual…

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ: BPMC ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 2 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Blueprint Medicines. The company has an average price target of $97.8 with a high of $120.00 and a … Full story available on Benzinga.com

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter